KALAMAZOO, Michigan — Armune BioScience, which is developing protein-based diagnostic tests for certain cancers, added $400,000 through debt and other securities, according to a filing with the Securities and Exchange Commission.
The funding follows a $1.1 million angel round the 1-year-old startup closed in August 2008. Soon after that round the company opened a research lab at the Medical Research Institute in Ann Arbor.
Armune is developing a test to detect cancer by finding evidence of the immune response to cancer. Its first product tests for prostate cancer, but it is also developing lung and breast-cancer tests.
Consultants: Help Define What’s Next In Healthcare Benefits
Help shape the future of healthcare benefits by sharing your insights.
Among the company’s investors is Apjohn Group. It has received money from the Michigan Pre-Seed Capital Fund.